Caroline is CEO and founder of Elasmogen, a company that discovers and develops soloMER biologics for the treatment of inflammatory diseases and cancer. She has successfully led teams at Wyeth and Pfizer in Global Bio-therapeutic Technologies progressing early platform technologies to late stage clinical development. She played a key part of the acquisition team that successfully exited the business to Wyeth Inc. She has been awarded a prestigious Royal Society of Edinburgh Enterprise Fellowship, is a doctoral graduate from the University of Aberdeen in Biochemistry and an MBA (distinction) from Robert Gordon's University, Business School. Caroline is a member of the Enterprise Skills and Strategy Board, is a Senior Associate for the Entrepreneurial Business School, Edinburgh and Entrepreneur in Residence for Queen's University Belfast.

Caroline Barelle


Science, Industry and Translation CommitteeJanuary 2022 - December 2024Member